Abstracts tagged "Cohort Study"

Abstract Number: 1100 • ACR Convergence 2025
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Gregory Challener¹, Chen Wang², David Gritsch², Ilana Usiskin³, Zandra E. Walton¹, Minna Kohler⁴, Hyon K. Choi⁵ and Jeffrey Sparks⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell…
Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Zeyu Tang¹ and Abhijeet Danve², ¹Yale School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…
Abstract Number: 0385 • ACR Convergence 2025
Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study
Simran Nimal¹, Meridith Balbach², Aslam Fawad¹, Midori Nishio³ and Erin Chew², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Vanderbilt University, Nashville, TN, ³John Muir Specialty Medical Group, Lafayette, CA
Background/Purpose: Musculoskeletal ultrasound (MSKUS) is a valuable tool for early detection and management of inflammatory arthritis.(1) Although integrated into rheumatology guidelines, training programs, and classification…
Abstract Number: 0158 • ACR Convergence 2025
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Lesley Jackson¹, jerrod anzalone², Rahima Begum³, Fazlur Rahman¹, Namrata Singh⁴, Londyn Robinson⁵, Kaleb Michaud², Kenneth Saag⁶, Jasvinder Singh⁷, Rena Patel¹ and Maria I. ("Maio") Danila⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Washington, Bellevue, WA, ⁵University of Washington, Seattle, WA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Baylor College of Medicine, Houston, TX, ⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Stevie Barry¹, Katie McMenamin², Austin Wheeler³, Bryant England³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Rui Xiao¹, Sylvanus Toikumo¹⁴, Henry Kranzler¹⁴, Rachel Kember¹⁴, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls³, Joshua Baker¹ and Thomas Riley¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston Medical Center, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 2080 • ACR Convergence 2025
Foot laterality does not modify outcome of knee and/or hip osteoarthritis
Simon Fondin¹, Armand Eyraud¹, Estelle Nkonda¹, Anne-Christine Rat², Bruno Fautrel³, SELLAM JEREMIE⁴, Christian Roux⁵, Jacques Pouchot⁶, Joel Coste⁷, Francis Guillemin⁸ and Alain SARAUX⁹, ¹Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁵CHU Nice, Nice, France, ⁶AP-HP, Rueil Malmaison, France, ⁷APHP, Paris, France, ⁸CHU Nancy, Nancy, France, ⁹CHU Brest, Brest, France
Background/Purpose: Hip and knee osteoarthritis (OA) are among the leading causes of global disability. Global OA is more prevalent on the right side. This discordance…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Vasileios Kyttaris¹, Dan Persons², Gelareh Atefi³ and Mawuena Binka⁴, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Trio Health, Louisville, CO, ³AstraZeneca, Wilmington, DE, ⁴Former Employee of AstraZeneca, Wilmington, DE
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…
Abstract Number: 1346 • ACR Convergence 2025
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
YU Chen¹, Chien-Sheng Wu², Jacob Shujui Hsu³ and Pei-Lung Chen⁴, ¹Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., New Taipei City, Taiwan (Republic of China), ²Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C., New Taipei city, Taiwan (Republic of China), ³Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei city, Taiwan (Republic of China), ⁴Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan (Republic of China)
Background/Purpose: Multiple Single-Nucleotide Polymorphisms (SNPs), including those in the methotrexate and azathioprine metabolic pathways, are associated with poor response to conventional disease-modifying anti-rheumatic drugs (cDMARDs)…
Abstract Number: 1099 • ACR Convergence 2025
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Grace Haeun Lee¹, Gregory Challener², Janeth Yinh³, Jeffrey Sparks⁴, Kerry L. Reynolds⁵, Donald P. Lawrence⁵, Meghan J. Mooradian⁵, Ryan J. Sullivan⁵, Hyon K. Choi⁶ and Minna Kohler⁷, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) has been recommended [1-3] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), preferred due to its low immunosuppressive effect. However,…
Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay¹, Shu Wang², Huong Trinh¹, Yunru Huang¹, William Pendergraft¹ and Brad Rovin³, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research LLC, Hoboken, NJ, ³The Ohio State University, Columbus, OH
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 2657 • ACR Convergence 2025
Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: GLP-1 receptor agonists (GLP-1RAs) are increasingly utilized in diabetes mellitus management due to their glucose-lowering and cardiovascular benefits. However, the effect of GLP-1RAs on…

« Previous Page
1
…
7
8
9
10
11
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].